Which medications are known to cause elevated plasma ammonia levels?

Medications That Cause Elevated Ammonia Levels

Valproic acid is the most clinically significant medication that causes elevated ammonia levels, and this should be the primary drug-induced cause considered in any patient presenting with hyperammonemia. 1

Primary Offending Medications

Valproic Acid (Valproate)

Valproic acid causes hyperammonemia through competitive inhibition of N-acetylglutamate synthase (NAGS), a key enzyme in the urea cycle 1. This is the most well-established drug-induced cause of hyperammonemia:

• Occurs commonly: 27.8% of patients on valproate develop hyperammonemia (ammonia >93 µg/dL), with 5.1% developing severe hyperammonemia (>150 µg/dL) 2
• Dose-dependent effect: Each 1 mg increase in valproate dosage increases hyperammonemia risk by 0.1% 2
• Serum valproate concentrations correlate positively with serum ammonia levels 3
• Can progress to hyperammonemic encephalopathy (HE), particularly when ammonia levels exceed 150 µg/dL 3

Risk is significantly amplified by concomitant medications:

• Phenytoin: 6.4-fold increased odds of hyperammonemia when combined with valproate 3
• Topiramate: Significantly associated with valproate-related hyperammonemia 3
• Liver enzyme-inducing antiepileptic drugs: Increase hyperammonemia risk 2
• Antipsychotic drugs: Increase hyperammonemia risk 2
• Salicylates: Potentiate valproate-induced hyperammonemia 4

Carbamazepine

Carbamazepine can cause hyperammonemia, though less commonly than valproate 5. A documented case showed:

• Ammonia level of 127 µg/dL (reference range 19-60 µg/dL) after 3 weeks of therapy
• Symptoms included severe agitation and aggressive behavior
• Resolved within 4 days of drug discontinuation with lactulose treatment 5

L-Asparaginase

All patients receiving L-asparaginase develop elevated blood ammonia levels 6:

• Elevation begins 2 days after treatment initiation
• Peak levels (194-446 µmol/L, median 300 µmol/L) occur at median of 4 days
• Returns to normal after median of 5 days following drug withdrawal
• 13% (3 of 23 patients) developed hepatic encephalopathy 6
• Highest risk in elderly patients, those with pre-existing liver disease, or history of heavy alcohol use 6

Clinical Monitoring Recommendations

For patients on valproic acid:

• Monitor serum ammonia levels, especially when:
  • Adding phenytoin or topiramate
  • Patient has epilepsy, congestive heart failure, or liver disease 3
  • Symptoms develop: nausea, fatigue, somnolence, ataxia, consciousness disturbance 2

For patients on L-asparaginase:

• Close blood ammonia monitoring is mandatory given 100% incidence of elevation 6
• Monitor coagulation function and liver enzymes concurrently 6

For patients on carbamazepine:

• Consider ammonia monitoring if behavioral changes or encephalopathy symptoms develop 5
• Be particularly vigilant in patients with prior valproate-induced hyperammonemia 5

Critical Pitfalls to Avoid

1. Do not assume normal valproate levels exclude hyperammonemia: The case report showed hyperammonemia with subtherapeutic carbamazepine levels (3.9 µg/mL, reference 4-12 µg/mL) 5

2. Do not delay treatment while waiting for ideal sample conditions: Samples not kept chilled or processed promptly should still be analyzed with appropriate interpretive comments, as delayed diagnosis of hyperammonemia has serious clinical consequences 7

3. Do not overlook drug interactions: The combination of valproate with phenytoin, topiramate, or salicylates substantially increases hyperammonemia risk beyond valproate alone 3, 4

4. Do not ignore mild elevations in asymptomatic patients: Most patients with valproate-induced hyperammonemia are asymptomatic, but this can progress to encephalopathy 2